SOMAÍ Pharmaceuticals, a Portugal-based marijuana company, has partnered with Cosma S.A., a Polish company focused on cannabis-based pharmaceutical advancements, to introduce a range of advanced cannabis-based products to Polish patients. The partnership aims to improve access to high-quality, innovative cannabis-based therapies for Polish patients, with Cosma S.A. acting as the marketing authorization holder (MAH) for both companies’ products.